Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravitreal Conbercept vs Conbercept + Dexamethasone for Retinal Vein Occlusion–Related Macular Edema
ChiCTR2500095700Phase 4Not yet recruiting
- Sponsor
- Eye and ENT Hospital of Fudan University
- Start
- Jan 2025
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of conbercept in Vein occlusion (RVO) and macular edema (2 arms), sponsored by Eye and ENT Hospital of Fudan University. Primary endpoints: Best corrected visual acuity and Central foveal thickness. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
conbercept
03
Conditions
Vein occlusion (RVO)macular edema
Beyond the preview
Go deeper on ChiCTR2500095700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500095700.